Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons

PLoS ONE

Volumn 2, Issue 4, 2007, Pages

  Taubert, Dirk ^a   Grimberg, Gundula ^a   Stenzel, Wermer ^a   Schömig, Edgar ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLO(HISTIDYLPROLINE); ORGANIC CATION TRANSPORTER 3; SALSOLINOL; TETRAZOLIUM; TYROSINE 3 MONOOXYGENASE; CYCLOPEPTIDE; DOPAMINE; HISTIDYL-PROLINE DIKETOPIPERAZINE; NEUROPROTECTIVE AGENT; ORGANIC CATION TRANSPORTER; PIPERAZINE DERIVATIVE; SLC22A2 PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROMODULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA; TANDEM MASS SPECTROMETRY; ANIMAL; CYTOLOGY; DRUG EFFECT; METABOLISM; MIDDLE AGED; NERVE CELL; PROTEIN BINDING; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOPAMINE; HUMANS; MIDDLE AGED; NEURONS; NEUROPROTECTIVE AGENTS; ORGANIC CATION TRANSPORT PROTEINS; PEPTIDES, CYCLIC; PIPERAZINES; PROTEIN BINDING; RATS; SUBSTANTIA NIGRA; TANDEM MASS SPECTROMETRY; TYROSINE 3-MONOOXYGENASE;

EID: 34548030734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000385     Document Type: Article

References (26)

1. Lesch KP, Murphy DL (2004) Molecular genetics of transporters for norepinephrine, dopamine, and serotonin in behavioral traits and complex diseases. In: Bröer S, Wagner CA, eds (2004) Membrane Transporter Diseases. New York: Kluwer Academic/Plenum Publishers. pp 349-364.
2. Jonker JW, Schinkel AH (2004) Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308: 2-9.
3. Koepsell H (2004) Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 25: 375-381.
4. Hatzopoulos AK, Stoykova AS, Erselius JR, Goulding M, Neuman T, et al. (1990) Structure and expression of the mouse Oct2a and Oct2b, two differentially spliced products of the same gene. Development 109: 349-362.
5. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, et al. (1998) Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54: 342-352.
6. Schomig E, Lazar A, Grundemann D (2006) Extraneuronal moricamine transporter and organic cation transporters 1 and 2: A review of transport efficiency. Handb Exp Pharmacol: 151-180.
7. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, et al. (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80: 486-501.
8. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, et al. (1998) Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem 273: 30915-30920.
9. Prasad C (1998) Limited proteolysis and physiological regulation: an example from thyrotropin-releasing hormone metabolism. Thyroid 8: 969-975.
10. Ikegami H, Prasad C (1990) Neuropeptide-dopamine interactions. V. Cyclo(His-Pro) regulation of striatal dopamine transporter complex. Peptides 11: 145-148.
11. Toth BE, Bodnar I, Homicsko KG, Fulop F, Fekete MI, et al. (2002) Physiological role of salsolinol: its hypophysiotrophic function in the regulation of pituitary prolactin secretion. Neurotoxicol Teratol 24: 655-666.
12. Mravec B (2005) Salsolinol, a derivate of dopamine, is a possible modulator of catecholaminergic transmission: a review of recent developments. Physiol Res.
13. Storch A, Ott S, Hwang YI, Ortmann R, Hein A, et al. (2002) Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol 63: 909-920.
14. Naoi M, Maruyama W, Akao Y, Yi H (2002) Dopamine-derived endogenous; N-methyl-(R)-salsolinol: its role in Parkinson's disease. Neurotoxicol Teratol 24: 579-591.
15. Grundemann D, Babin-Ebell J, Martel F, Ording N, Schmidt A, et al. (1997) Primary structure and functional expression of the apical organic cation transporter from kidney epithehal LLC-PK1 cells. J Biol Chem 272: 10408-10413.
16. Antkiewicz-Michaluk L, Krygowska-Wajs A, Szczudlik A, Romanska. I, Vetulani J (1997) Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology. Biol Psychiatry 42: 514-518.
17. Naoi M, Maruyama W, Dostert P, Hashizume Y (1997) N-melhyl-(R)salsolinol as a dopaminergic neurotoxin: from an animal model to an early market of Parkinson's disease. J Neural Transm Suppl 50: 89-105.
18. Faden AI, Movsesyan VA, Knoblach SM, Ahmed F, Cernak I (2005) Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology 49: 410-424.
19. Leabman MK, Huang CG, Kawamoto M, Johns SJ, Stryke D, et al. (2002) Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12: 395-405.
20. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium, thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.
21. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
22. Storch A, Ludolph AC, Schwarz J (1999) HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism. Neurochem Int 35: 393-403.
23. Caccamo D, Campisi A, Curro M, Li Volti G, Vanella A, et al. (2004) Excitotoxic and post-ischemic neurodegeneration: Involvement of transglutaminases. Amino Acids 27: 373-379.
24. Augustin M (1966) Über 2,5-Diketopiperazine, II. Die Umsetzung des 2,5-Diketopiperazins mit Aldehyden und Nitrosoverbindungen. J Prakt Chem 32: 158-166.
25. Hayer-Zillgen M, Bruss M, Bonisch H (2002) Expression and pharmacological profile of the human organic cation transporters hOCT1 hOCT2 and hOCT3. Br J Pharmacol 136: 829-836.
26. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia. nigra regional selectivity. Brain 114(Pt 5): 2283-2301.